This is a working overview of thymus extract, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
== Awards and honors == Csaba Horváth Medal of the Connecticut Separation Science Council (2001) Keene P. Dimick Award in Chromatography of the Society of Analytical Chemists of Pittsburgh (1998) Jubilee Award of the International Symposium on Capillary Chromatography (1998) Golden Diploma from Budapest Technical University (1995) Elected Honorary Member, Hungarian Chemical Society (1992) Marcel J. E. Golay Award of the International Symposium on Capillary Chromatography (1992) M. S. Tswett Medal of the Russian Chromatography Society (1991) Pioneer in the Development of Analytical Instrumentation of the first James L. Waters Symposium at the 41st PittCon (1990) National Award in Chromatography of the American Chemical Society (1985) A. J. P. Martin Gold Award of the Chromatography Discussion Group (1982) Anniversary Medal of Tartu University (Estonia, 1981) L.S. Palmer Award of the Minnesota Chromatography Forum (1980) Anniversary M.S. Tswett Chromatography Medal of the All-Union Scientific Council on Chromatography of the USSR Academy of Sciences (1979) M.S. Tswett Award in Chromatography of the International Symposium on Advances in Chromatography (1978)
McDivitt must have switched to the VOX setting somewhere around the time White was exiting the spacecraft, because at that point, for most of the EVA, neither he nor White responded either to the Hawaii CAPCOM, or to the Houston CAPCOM, Gus Grissom. Grissom tried to talk to Gemini 4 a total of 40 times in 13 minutes before he got a response. Tied to a tether, White floated out of the spacecraft, using a Hand-Held Maneuvering Unit (informally called a "zip gun") which expelled pressurized oxygen to provide thrust for controlling his travel. He went 4.6 meters (15 ft) out and began to experiment with maneuvering. He found it easy, especially the pitch and yaw, although he thought the roll would use too much gas. He maneuvered around the spacecraft while McDivitt took photographs. White enjoyed the experience, but exhausted the HHMU gas sooner than he would have liked. White was running up against two factors which constrained the time for his EVA: loss of signal from the Bermuda tracking station and crossing the solar terminator. The flight controllers were becoming increasingly frustrated with their inability to remind White of the time constraint, because they didn't want the first EVA to be performed in darkness or out of communication with Earth. Finally McDivitt decided to take his microphone off VOX:
== Further reading == Açbay O, Celik AF, Kadioğlu P, Göksel S, Gündoğdu S (1999). "Helicobacter pylori-induced gastritis may contribute to occurrence of postprandial symptomatic hypoglycemia". Dig. Dis. Sci. 44 (9): 1837–42. doi:10.1023/A:1018842606388. PMID 10505722. S2CID 22096584.
=== Societal === In a 2012 University of Amsterdam study of 120 women, the women's luteal phase (higher levels of progesterone, and increasing levels of estrogen) was correlated with a lower level of competitive behavior in gambling and math contest scenarios, while their premenstrual phase (sharply decreasing levels of progesterone, and decreasing levels of estrogen) was correlated with a higher level of competitive behavior.
Sources: en.wikipedia.org
== Formation and ecological succession == Cold seeps occur over fissures on the seafloor caused by tectonic activity. Oil and methane "seep" out of those fissures, get diffused by sediment, and emerge over an area several hundred meters wide. Methane (CH4) is the main component of natural gas. But in addition to being an important energy source for humans, methane also forms the basis of a cold seep ecosystem. Cold seep biota below 200 m (660 ft) typically exhibit much greater systematic specialization and reliance on chemoautotrophy than those from shelf depths. Deep-sea seeps sediments are highly heterogeneous. They sustain different geochemical and microbial processes that are reflected in a complex mosaic of habitats inhabited by a mixture of specialist (heterotrophic and symbiont-associated) and background fauna.
Robert Boyle improved Guericke's design and conducted experiments on the properties of vacuum. Robert Hooke also helped Boyle produce an air pump that helped to produce the vacuum. By 1709, Francis Hauksbee improved on the design further with his two-cylinder pump, where two pistons worked via a rack-and-pinion design that reportedly "gave a vacuum within about one inch of mercury of perfect." This design remained popular and only slightly changed until well into the nineteenth century.
insulin and IGF-1 driven proliferation of keratinocytes and fibroblasts fibroblast growth factor receptor abnormalities in hereditary forms transforming growth factor-α overexpression in malignancy-associated cases, activating the epidermal growth factor receptor Sweat, friction and occlusion may accentuate lesion development in predisposed areas.
=== Glutamatergic signaling === Glutamate is the brain's major excitatory neurotransmitter and its release can trigger the depolarization of postsynaptic neurons. AMPA and NMDA receptors are two ionotropic glutamate receptors involved in glutamatergic neurotransmission and essential to learning and memory via long-term potentiation. While AMPA receptor activation leads to depolarization via sodium influx, NMDA receptor activation by rapid successive firing allows calcium influx in addition to sodium. The calcium influx triggered through NMDA receptors can lead to expression of BDNF, as well as other genes thought to be involved in LTP, dendritogenesis, and synaptic stabilization.
An aphrodisiac is a substance that increases libido, sexual desire, sexual attraction, sexual pleasure, or sexual behavior. These substances range from a variety of plants, spices, and foods to synthetic chemicals. Natural aphrodisiacs, such as cannabis or cocaine, are classified into plant-based and non-plant-based substances. Synthetic aphrodisiacs include MDMA and methamphetamine. Aphrodisiacs can be classified by their type of effects (psychological or physiological). Aphrodisiacs that contain hallucinogenic properties, such as bufotenin, have psychological effects that can increase sexual desire and sexual pleasure. Aphrodisiacs that have smooth muscle relaxing properties, such as yohimbine, have physiological effects that can affect hormone concentrations and increase blood flow. Substances that have the opposite effects on libido are called anaphrodisiacs. Aphrodisiac effects can also be due to the placebo effect. Both males and females can potentially benefit from the use of aphrodisiacs, but they are more focused on males, as their properties tend to increase testosterone concentrations rather than estrogen concentrations. This is in part due to the historical context of aphrodisiacs, which focused solely on males. Only recently has attention been paid to understanding how aphrodisiacs can aid female sexual function. In addition, cultural influences on appropriate sexual behavior of males and females also play a part in the research gap.
Sources: en.wikipedia.org
On sharp reverse curves, the buffers can become locked by slipping over, and on to, the back of each other. Although careful track design makes this a rare occurrence, a series of derailments at Stuttgart Central Station in 2012 were caused by buffer-locked wagons. Buffer-lock could occur on very sharp switches on rolling stock with the older, rounded buffers. Newer buffers are rectangular and are wider than they are tall. Buffers and chain couplers allow curves to have around 150 m (492 ft) radius, but sharp S-curves are not allowed. If it were not for the couplers, much sharper curves could be allowed, provided the train is not too long.
The city of Detroit, in the U.S. state of Michigan, went through a major economic and demographic decline that began in the mid 20th century and lasted for decades. The population of the city fell from a high of 1,849,568 in 1950 to 639,111 in 2020, removing it from the top 20 of US cities by population for the first time since 1850. Local crime rates are among the highest in the United States (even though the overall crime rate in the city has seen a decline during the 21st century), and vast areas of the city are in a state of severe urban decay. In 2013, Detroit filed the largest municipal bankruptcy case in U.S. history, which it successfully exited on December 10, 2014. As of 2017, the median household income is rising, and criminal activity is decreasing by 5% annually as of 2017. In 2025, the US Census Bureau reported that Detroit's population had grown for the second straight year, beginning the long process of reversing the decline of the city's population.
Goodman impelled technical and procedural progress and popularized the open rhinoplasty approach. In 1987, Gunter reported the technical effectiveness of the open rhinoplasty approach for performing a secondary rhinoplasty; his improved techniques advanced the management of a failed nose surgery. In early 2021, it was reported that a trend that involved getting a rhinoplasty had emerged on the social media platform TikTok. The trend became known as the #NoseJobCheck trend and involved users of the platform posting videos that showed how their noses looked before and after their rhinoplasty surgeries, with a specific audio soundtracking the video. From October 2020 to January 2021, the #NoseJobCheck audio had been used in over 120,000 videos and videos with the #NoseJobCheck hashtag had accumulated over one billion views.
== Safety == Frozen vegetables can be contaminated with certain pathogens like Listeria. For people at risk of listeriosis illness (those with weakened immune systems and pregnant people), it is recommended that frozen vegetables be cooked before consumption to reduce the risk. With that said, the risk of contamination is very low. Food safety regulations limit the amount of pathogens such as Listeria to safe limits (100 CFU/g in Europe). Contamination with Listeria is rare and results in product recalls or alerts. Although there is a risk of Listeria starting to grow during improper thawing to exceed the 100 CFU/g limit, the risk of infection remains much lower than other kinds of ready-to-eat food such as smoked fish, cooked meat, and soft cheese.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.